
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific has demonstrated robust growth across several product lines, with Watchman sales increasing by 35% year-over-year and electrophysiology (EP) experiencing a striking 63% growth, indicative of strong market demand and competitive positioning. The company's guidance for Q4 suggests organic sales growth of 11-13%, coupled with expected GAAP EPS of $0.48-$0.52, reflecting a solid financial outlook driven by effective product adoption and a diversified portfolio. Additionally, significant future contributions are anticipated from growth areas such as Nalu, projected to surpass $60 million in sales by 2025, along with continued expansion in coronary therapies and diagnostics, bolstering a positive long-term growth trajectory.
Bears say
Boston Scientific is facing a challenging financial environment marked by anticipated foreign exchange headwinds of approximately $0.04 for the full year, indicating potential revenue pressure. The firm's reliance on mature markets within its Cardiac Rhythm Management (CRM) and Drug-Eluting Stents (DES) portfolios, coupled with pricing pressures, raises concerns about sustained growth as sales may struggle to meet internal and consensus expectations. Additionally, the company's revenue performance has shown mixed results, with significant setbacks in key segments such as Urology and Interventional Cardiology, which may hinder its future growth trajectory if product integrations do not proceed smoothly.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares